Reproducibility Study of Over Active Bladder Symptom Score [OABSS]
NCT ID: NCT00901251
Last Updated: 2011-03-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2009-01-31
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reproducibility Study of Overactive Bladder Symptom Score [OABSS]
NCT01122550
Reproducibility Study of OABSS and Its Response to Treatment
NCT02667470
Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients
NCT00985387
A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment
NCT01122563
A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients
NCT00840645
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 1 urgency episode in last 3 days
* Symptoms of OAB as verified by the screening 3-day bladder diary, defined by:
* Number of micturition ≥8 times/day
* Number of urgency episode in 3 days ≥1
Exclusion Criteria
* Symptomatic urinary tract infection, chronic inflammation
* Diabetic neuropathy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma China, Inc.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Astellas Pharma, Inc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Use Central Contact
Role: STUDY_CHAIR
Astellas Pharma China, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing, , China
Chongqing, , China
Shanghai, , China
Shenyang, , China
Wuhan, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VESOABCN02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.